Subject Index. Arrhenius equation 35 autoradiography 249

Transcription

1 Absence seizures 221 EEG telemetry efficacy of clonazepam 247 efficacy of ethosuximide absorption 13, 15, 262 competition 50 accumulation 223 acetylpheneturide concentration in CSF 328 ratio CSF/serum 328 concentration in serum 328 dosage 328 activation energy adjunctive medication 4, 49 affinity constant 33, 34, 47 analytical methods 13, 56, comparison , 340 development of a matrix reference standard extraction procedure 289, 290, 337, 338, 339 methylation partition coefficients 290, 314 quality 16 quality control 16 Quality Control Scheme acceptability of results 301 accuracy of methods 299, 300, 301 reliability of methods 294, 301 recovery 314,319 relevance 19,58,62 reliability 287, 298 report, review 286, 293 request form 339 sample volume 4,43,287,288 stationary phases 287 time of sampling 288, 289 anti-epileptic drugs analytical method, see above and individual drug clearance 6 relative clearance 6 combination of 43, 49 concentration in plasma 5 determination in saliva 107, 135, 146 anti-epileptic drugs dictionary chemical names drug synonyms non-proprietary names dosage 5 Michaelis-Menten kinetics 143 number prescribed 4, 50 prediction 136, 137, 143 transport plasma/brain, CSF 145 anti-epileptic medication distribution 4 apparent volume of distribution 3, 12 Arrhenius equation 35 autoradiography 249 Barbiturates benzodiazepines 30 interaction with phenytoin metabolism 89 binding affinity 34 of amphetamines, antidepressants, barbiturates and benzodiazepines 35 bioavailability 15 biotransformation see also metabolism of individual drug induction 37,39 inhibition 39 microsomal enzyme system 34-40, 197, 210 mixed function oxidase system 40 body surface, equation of du Bois and du Bois 4 Calculation, individual dosage regimen of phenytoin carbamazepine 25, absorption 26, 160, 161, 164, 165, 166, 168,175,176,184,185,204,206,209, 212,213 influence of formulation 227 accumulation 254 analytical method 13,26,59,119,151, 152,159, 167,172,191,197,202,210, 211, ,

2 carbamazepine comparison partition coefficient 290, 291, 314 recovery 314 apparent volume of distribution 27, 168, 176 clearance 6,27,43, 168,211,212 relative clearance 6,2'7,43,212 clinical efficacy in controlled studies 215 in long-term treatment 215 concentration in CSF 171, 172, 176 ratio CSF/dosage 270 ratio CSF/serum or plasma 172, 173, 181,270, 328 concentration in serum/plasma 5, 43, 151, 161, 164, 168, , , ,212,228,270,328 clinical control 151 and EEG 154 diurnal fluctuation 181, 183, 184, 185,186,206,207,208,209,263, 267, 288, 289 free fraction 270 influence of co-medication 186,197, influence of formulation relation to dosage 102, , ,197, ,213,214, 267,270 side-effects 151, 152, 154, 157, 175, therapeutic concentration 27, 151 therapeutic effect 151, 153, 173,212, 215, 216 therapeutic range 151, 156, 181, 186, 194 distribution in anti -epileptic medication 4,43 distribution in the body 26, 166, 185 regional cerebral distribution 26 dosage 5, 168, 190, 270, 328 dose frequency 214,267 drug interaction 13,27,177, , , 204 induction of oxidative enzymes 195, 199,204,210 efficacy in generalized focal, complex partial seizure or absence attacks 215 in psychomotor seizures , 215 elimination 161, 162, 163, 185 elimination rate 166 elimination rate constant 27, 168, 175 enterohepatic circulation 165, 206 excretion, via bile and faeces 160, 161, 162, 164, carbamazepine via urine 160, 161, 162, 164, 169, 170, 176 conjugated 169 non-conjugated 169 formulation 165, 206, 209, 225, 227 influence on serum concentration half-life time 27, 161, 164, 168, 175, 176, 177, 181, 182, 185, 207, 208, 209, 226,267 influence of co-medication 6, 186 interaction with phenytoin 90, 93 metabolism 27, 156, 159, 161, 164, 193, 194,199,204,213 autoinduction phenomenon 175, 177, 208, 210, 213 enzyme induction by phenobarbitone, phenytoin 226 metabolites 159, 160, 161, 162, 165, 166 excretion , 169, 170 stereo-chemistry 163 plasma protein binding 27, 167, 170, 171, 176, and co-medication 171 regional cerebral distribution 26 side-effects 152, 154, 157, 175, , 209, 214 time of sampling 13, 168,213 central stimulants 4 charting system 12, 44 chemical names of anti-epileptic drugs, dictionary chemical stability of drugs 17 chlordiazepoxide interaction with phenytoin 93 chlorpromazine influence on phenobarbitone serum concentration influence on phenytoin serum concentration clearance 3, 9 age dependency 8, 44 relative age dependency 3 clinical control and poly-pharmacy 49 clinical pharmacokinetic parameters 2-33 clonazepam absence seizures 247 accumulation 244, 250, 254 analytical method 12, 13, 242, accuracy 242 sensitivity 242 apparent volume of distribution 30, 253, 254, 255, 257, 258 basic kinetics 242, 243 biotransformation 243, 252, 253

3 364 clonazepam breakthrough in seizures 260 clearance, relative 30, 255, 257, 258 concentration in plasma/serum clinical effect , 258 correlation to dosage 243, 244, , 260 diurnal fluctuation 244 side-effects 245 therapeutic plasma concentration 13, 30,255 -time curve 38, 244, variation 244 distribution 4 in the body , 254, 258 in brain 245 drug interaction 13, 244, 245, 260 efficacy 30, 247 elimination rate 30, 257 excretion in urine 243 half-life time 30, 242, metabolism 252, 253 metabolites 243, 244, 253, 255 activity 244, 253, 260 excretion in urine 243, 253 plasma concentration 245 side-effects 245, 246, 260 and withdrawal symptoms 244, 260 protein binding 30 provocation of grand-mal on withdrawal 241, 260 side-effects 242, 245, 247, 248, 252 time of sampling 13 withdrawal and provocation of grandmal 241,260 co-medication 7, 8, 9, 15 and relative clearance 15 and therapeutic confidence 15 comparison of spectrophotometric and gas chromatographic analyses compartment open - model 2,27,169 compartment 1 (plasma) 2, 14 compartment 2 (tissues) 14 compliance 16, 44, 82, 143, 149, 173, 177 concept of molarity 309 controlled trial, design 80 cytochrome P and clonazepam concentration curve 38 and drug metabolism 34 mass decrease 37 mass increase by phenobarbitone 37 and phenobarbitone concentration curve 38 Desmethyldiazepam accumulation 254 analytical method 13 desmethyldiazepam drug interaction 13 therapeutic concentration 13 time of sampling 13 desmethyl-mesuximide analytical method recovery 126 Dettli, equation of 63 D-glucaric acid and enzyme induction 97,98 excretion 97 ratio to creatinine 97 diazepam absorption 30 analytical method 13 distribution 30 apparent volume of distribution 30 drug interaction 13 elimination rate 30, 44 half-life time, dependency on age 102 influence on phenobarbitone serum concentration on phenytoin serum concentration interaction with phenytoin 93 protein binding 30, 271 relative clearance 30 therapeutic plasma concentration 13, 30 time of sampling 13 dictionary of anti-epileptic drugs chemical names non-proprietary names synonyms difference spectrum of cytochrome P-450 enzyme 35 dihydro-dihydroxy-carbamazepine 159, 160, 176 analytical method 167, 191 excretion 162, 165, 167, 169, 170 formation of - 156, 159, 160, 164 stereo chemistry 162 dimethadione metabolite concentration in serum 328 dipropylacetamide 224, 228 biotransformation to dipropylacetate 224,228 dipropylacetate (DP A) absorption 28, 223, 224, 228, 229 influence of food intake 223 influence of formulation 223, 224, 233, 234 accumulation 29 analytical method 12, 13, 28, 224, 230 apparent distribution volume 29

4 : dipropylacetate clearance 6 age dependency 8, 13 clinical effect 232 concentration in plasma/serum 5 correlation with seizure frequency 234 diurnal variation 223,231,232, 234, 288,289 influence of co-medication 236 influence of formulation 224, relation to body weight 235 relation to dosage 233, 235 relative -, relationship with-dglucaric acid excretion 237 therapeutic concentration 13, 29, 30 distribution in anti-epileptic medication 4 distribution in the body 29 distribution in brain 29,40,241 coefficient brain/plasma 29 regional cerebral distribution 29 dosage 5, 233 dose regime 233, 234 drug interaction 13, 29 elimination rate 29,30 excretion in urine 225 formulation 223, 224, 229 and absorption 223, 224, 228 and biotransformation 224 disadvantages 229 and serum concentration 224, 225, half-life time 30, 229, 233 interaction with carbamazepine 238 phenobarbitone 238, 239, 240 phenytoin 238, 239 intoxication 238, 239 potentiation 239 metabolism 224 mode of action 29 side-effects 229, 233, 240 time of sampling 13 displacement interaction and distribution volume 271 dissociation constant 34 of amphetamines, antidepressants, barbiturates and benzodiazepines 35 distribution kinetics of anti-epileptic medication 2, 13 distribution of anti-epileptic medication 4 distribution volume 271 dosage, mean 5 individual - calculation for phenytoin dosage interval 3, 15 regimen 3,9 drug interaction 13, 15, benzodiazepines with phenytoin 89 carbamazepine with dipropylacetate 236,241 phenobarbitone 215 phenytoin 90, 93, 215 chlordiazepoxide with phenytoin 93 clonazepam with carbamazepine 246 phenobarbitone 246 phenytoin 245, 246 diazepam with phenobarbitone phenytoin 93, dipropylacetate with carbamazepine 238 phenobarbitone 238, 239, 240 phenytoin 238, 239 pheneturide with phenytoin 89, 93, 97, 98 phenobarbitone with carbamazepine 192, 193, 194, , ,226 dipropylacetate 236 phenytoin 23-24, 39, 91, 93, 94, 239 phenytoin with carbamazepine 192,193, 194, , , 226 clonazepam 244, 245 dipropylacetate 236 phenobarbitone 20, 39, 109, 239 primidone primidone with carbamazepine 192, 193 phenytoin 82-85, 91, 94 psychotropic with anti-epileptic drugs 50, 90, 93, succinimides with dipropylacetate 236 phenytoin 90, 94 sulthiame with phenytoin 67, 88-89, 92 drug metabolism influence of age 102 drug packaging 12, 44 drug synonyms, dictionary of anti-epileptic drugs du Bois and du Bois equation of - 4 Eclamptic seizures and clonazepam 248 elimination kinetics of elimination 2 first order 11 zero order 11 rate constant 3, 11 carbamazepine 27, 168, 175 clonazepam 30, 257 diazepam 30, 44 dipropylacetate 29, 30 ethosuximide 28 phenobarbitone 21

5 366 elemination phenytoin 23, 48, primidone 25 epilepsia partialis continua and clonazepam 255 epoxy-carbamazepine 159, 160, 176 analytical method 159,167,191,196, 197 anti-epileptic effect 177, 200, 211 apparent half-life time 175, 177, 211 concentration in serum/plasma 171, 172, 173, 174 relation to carbamazepine plasma levels 193, 194 excretion 161, 162, 165, 170, 211 conjugated 169 non-conjugated 169 formation of - 156, 159, 160, 164, 179 protein-binding 170, 171 equation of Arrhenius 35 Augsberger 18 Clark 18 Dettli 63 du Bois and du Bois 4 Fried 18 Young 18 ethosuximide absorption 27 influence of formulation 223 analytical method 13,27, , matrix reference standard 305 partition coefficient 314 apparent volume of distribution 27,28 bio-availability dependence on formulation clearance 6 age dependency 8, 13, 28 sex difference 6 concentration in CSF 328 concentration in plasma/serum 5, 218, clinical effect dependence on formulation 222 diurnal fluctuation 107,288 effect on the EEG 218,219 therapeutic concentration 13, 28 therapeutic range 85 distribution in anti-epileptic medication 4 distribution in the body 27 dosage 5, 28, 328 elimination rate 28 environment 15 ethosuximide formulation and absorption 223 and serum concentration half-life time 28 interaction with phenytoin 90, 94 metabolism 28 protein binding 28, 271 and psymosis 142 time of sampling 13 ethotoin absorption 113, 114 analytical method 111, , anti-epileptic activity 122 biotransformation 122, 123 concentration in CSF 328 ratio CSF/serum 122, 328 concentration in plasma/serum 113, 119, 120, 122, 328 diurnal fluctuation 113, 114 relation to dosage 120, 328 dose frequency 123 elimination rate 112 half-life time 120, 123 kinetics of elimination 113, 114, 123 side-effects 111, 122 Experimental Homogeneous Enzyme Immuno-Assay (EMIT) accuracy 334 crossreactivity 333 expense 336 microsamples 334 sensitivity 336 speed 334 stability 336 Food intake 12, 15 and absorption of dipropylacetate 223 formulation and absorption 262 free fraction 52, 107 and concentration in saliva 107, 146 and ratio CSF/serum 107 and therapeutic effect 262, 274 compare also "protein binding" of individual drug Grand-mal epilepsy and clonazepam 255 Half-life time 3 hydroxy-phenobarbitone analytical method during pregnancy 133 hydroxy-phenytoin (HPPH) analytical method in pregnancy 134

6 Iminostilben 176 analytical method 167,180,191 excretion 169, 170 presence in urine and plasma 179, 180 indication for (new) drugs induction phenomenon of metabolism 37, 39 infantile spasms and clonazepam 247 infusion rate 3 inhibition 39 interaction of anti-epileptic drugs 13 at the microsomal level see also drug interaction and individual drug intercurrent disease 16 International Classification of Epileptic Seizures 217 isoniazid interaction with phenytoin 47 Kinetics of distribution of anti-epileptic drugs 2 elimination of anti-epileptic drugs 2 Kupferberg analytical method of 56 Lennox-Gastaut-Syndrome 24 and clonazepam 248 liver enzyme induction 93, 94, 95, 97 and urinary D-glucaric acid excretion 97, 98, 236 Matrix reference standard concentration 305 development of medication error 44 medication (order) system 12, 13 mesuximide analytical method recovery 126 metabolism induction phenomenon by phenobarbitone 37, 39 metharbitone concentration in serum 328 dosage 328 methyl phenobarbitone analytical method , concentration in CSF 328 ratio CSF/serum 328 concentration in plasma 5, 145, 328 dosage 328 metabolism 145 methyl phenytoin partition coefficient 126 Michaelis-Menten equation 87 molarity concept of myoclonic seizures and clonazepam 247,255 Nitrazepam apparent volume of distribution 30 dose 30 half-life time 30 protein-binding 30 reciprocal elimination time constant 30 relative clearance 30 non-proprietary names, dictionary of anti-epileptic drugs nortriptyline, interaction with phenytoin metabolism 90, Pharmaceutical quality 16 pharmacokinetics of anti-epileptic drugs, clinical principles 2-3 pheneturide ratio CSF/serum 328 concentration in serum 328 dosage 328 interaction with phenytoin metabolism 89, 93, 97, 98 phenobarbitone absorption 20, 21, 268 accumulation in tissues 21, 82, 254 analytical method 13, 59, , ,275, 293, , 31'7-322, , accuracy comparison deviation 276 matrix reference standard 305 partition coefficient 125, 126, 290, 291 Quality Control Scheme recovery 126, reliability apparent volume of distribution 21 bioavailability 20 chemical stability in serum 308 clearance 6 age dependency 8, 19 relative clearance 6,7, 13,21 sex difference 6 concentration in brain 276,277 and regional distribution 282 correlation to plasma concentration 277,278

7 368 phenobarbitone ratio brain/plasma 277, 281 ratio white/grey matter 277 concentration in CSF 270, 328 ratio to dosage 270 ratio to serum concentration 270, 328, concentration in plasma/serum 5, 147, 174, 328 and cholesterol 47 and enzyme induction 239 diurnal fluctuation 107, 108, 268 influence of psychotropic drugs protein binding 21 relation to dosage 101, 268, 270 therapeutic concentration 13, 21, 85 therapeutic range 150 variation 47 concentration-time curve 38 D-glucaric acid excretion 237 ratio D-glucaric acid/creatinine 97, 237 distribution apparent volume of distribution 21 in the body 20 in brain regional cerebral distribution 100 distribution in anti-epileptic medication 4, 43 dosage 5,174,190,270,328 relation to plasma concentration 101, 270 drug interaction 13,20,47,91, 109 isoniazid, PAS 47, 100 elimination 48 rate constant 21 glucuronide fraction in urine 133, 134 half-life time 21, 268 influence of co-medication 6,7, intoxication 238 metabolism 48 in pregnancy 133, 134 partition coefficient brain/plasma 20 precipitation by freezing 308 protein binding 21 relative clearance 6, 21 influence of co-medication 6, 7 rela tionshi p with age 7, 13 time of sampling 13, 107 tolerance of the CNS 150 variation of serum concentration 47 phenylethylmalondiamide (PEMA) analytical method chemical stability in serum 308 concentration in CSF 145 phenylethylmalondiamide partition coefficient 126 plasma 145 protein binding 145, 271 recovery 126 phenytoin absorption 22, 48, 267 different preparations 263, 265, 266 accumulation in tissues 22, 254 analytical method 13,24,56,70,119, ,275,293, , , , accuracy comparison deviation 276 matrix reference standard 305 partition coefficient 125, 126,290,291 Quality Control Scheme recovery 126, reliability bioavailability 22, 267 chemical stability in serum 17,294, 306, 307 clearance 6, 22 age dependency 8, 13, 104 relative clearance 6, 22, 23, 43, 44 concentration in brain correlation to plasma concentration 277, 281, 282 influence of sampling time 281 fluctuation 283 and side-effects 283 partition coefficient brain/plasma 22 ratio brain/plasma 277,281 ratio grey matter/plasma 277, 281 ratio white/grey matter 276 concentration in CSF 269, 270, 278, 279, 328 correlation to plasma concentration 282 ratio to dose 269, 270 ratio to serum concentration 269, 270, 328 concentration in peripheral nerve 277 concentration in serum/plasma 5, 45, 46, 71, 73, 89, 174,269,270, 328 age dependency 47, and cholesterol 47 diurnal fluctuation 65, 66, 103, 107, 267, 288 dosage dependency 100, 101, 104 dosage format 78 free fraction 269 and pharmacological effects 278, 279 variation 269

8 phenytoin influence of formulation 265,266,267 influence of psychotropic drugs in intoxication 239 in pregnancy 134 ratio to dosage 269, 270 and age 66, 67, 71 sex difference 46, 47 therapeutic effect 13,23, 51, 71, 278 therapeutic range 51, 58, 71, 85,293 time curve, influence of formulation 265, 266 toxicity 51, 68, 71 variation 47 weight dependency 72-74, 76, 87 D-glucaric acid excretion 237 ratio D-glucaric acid/creatinine in urine 97,237 dissolution in plasma 307 distribution in the body 22 in brain 22,276 regional cerebral distribution 22 distribution in anti-epileptic medication 4,43 distribution volume 106 dosage 5,45,174, 190,270,329 therapeutic dosage schedule 24 dose frequency , 267 drug interaction 22,23-24, 47, 51, 67, isoniazide, PAS 47,100 elimination rate 23, 48, influence of age 105 formulation, different preparations 225, 263 influence on absorption 225, 228, 265 influence on clinical control 267 influence on intoxication 267 half-life time 23, 63, 65, 88, 266, 267 in pregnancy 134 intoxication 238, 239 maximum metabolic capacity 24 metabolism 22, 48, 101 dependency on age 105 dependency on dosage 99 in pregnancy 134 ratio HPPH/phenytoin in urine partition coefficient brain/plasma 22 pharmacokinetics linear 23 non-linear 11, 24 protein binding 23, 106,271,278 and co-medication 271 in disease phenytoin in neonates 271 and teratological effects 217 ratio p-hydroxy-phenytoin (HPPH) to phenytoin in urine 88, 89, 90, 91, 93, 94,95,96 relative clearance 6, 23 age dependency 44 influence of co-medication 6, 22 sex difference 6, 43 sa tura tion kinetics 104 and liver enzyme induction 93, 94, 95,97,106 serum concentration-time curve 265 influence of formulation 265, 266 stability in serum 17, 294, 306, 307 time of sampling 13, 107 Phenytoin Quality Control Scheme, results photic epilepsy and clonazepam 248, 255 plasma concentration of anti-epileptic drugs, mean 5 factors influencing 9, 12, 15 and therapeutic effect 51 poly-pharmacy, problems of primidone absorption 24 analytical method 13, 59, 293, , , accuracy 300 matrix reference standard 305 partition coefficient 125, 126, 290, 291 Quality Control Scheme recovery 126, 127 reliability 300 apparent volume of distribution 25 chemical stability in serum 308 clearance 6 rela ti ve clearance 6 clinical control 146, 147, 148, 149 compliance 146 concentration in brain ratio brain/plasma 281 concentration in CSF 145, 328 concentration in plasma/serum 5, 328 diurnal fluctuation 149 protein binding 145, 271 therapeutic concentration 13, 25, 85, 149 distribution apparent volume of distribution 25 in the body 25 regional cerebral distribution 25 distribution in anti-epileptic medication 4,43

9 370 primidone dosage 5, 190, 328 therapeutic dosage schedule 25 drug interaction 82-85, 91 elimination rate 25 half-life time 25 metabolism 24, 25 in hepatitis 149 metabolites 145, 146, 147, 148 ratio phenobarbitone/primidone protein binding 145,271 ratio phenobarbitone/primidone time of sampling 13, 107 protein binding of anti-epileptic drugs 52, 271, determination 262, 2'76 relation to concentration in brain 274 relation to quantity of plasma proteins 273 and toxicity 273 psychomotor seizures, clinical effect of carbamazepine , 215 psychotropic drugs 136 interaction of 50, Quality Control Scheme Quality Control and Standardization Ratio D-glucaric acid/creatinine 97 ratio p-hpph: phenytoin in urine 88-93,95 regimen, dosage - 3,9 individual dosage of phenytoin relation between clearance and body weight 3 relative clearance 3 report on worksheets request form 10, 339 Rule of Augsburger 18,19 Clark 18 du Bois and du Bois 4 Fried 18 Young 18,19,25 Sample volume 13 sulthiame analytical method and cerebral concentration of phenytoin 98 interaction with phenytoin metabolism 88,92 distribution volume 98 liver microsomal enzymes 98 role in treatment summing up 342 Svensmark and Kristensen, analytical method of - 56 comparison with Kupferberg's method interferences 58 Temporal lobe epilepsy and clonazepam 255 therapeutic concentration therapeutic range 13 therapeutic effect measurement 17 number of drugs 53 s thioridazine influence on phenobarbitone serum concentration influence on phenytoin serum concentration time of sampling 12, 85, 86, 107, 109 tissue binding 271 tolerance 50 toxicity 52 and poly-pharmacy 49 and plasma concentration 49 s transport plasma/brain/csf 145 trimethadione concentration in serum 328 dosage 328 "Unit dose" medication system 13, 44 units of results 309 Various aspects

10 Handbuch der experimentellen Pharmakologie Handbook of Experimental Pharmacology Vol. 4: General Pharmacology Vol. 10: Die Pharmakologie anorganischer Anionen Vol. 11: Lobelm und Lobehaalkaloide Vol. 12: Morphin und morphinlthnlich wirkende Verbindungen Vol. 13: The Alkali Metal Ions in Biology Vol. 14: The Adrenocortical Hormones Vol. 15: Cholinesterases and Anticholmesterase Agents Vol. 16: Erzeugung von Krankheitszustanden durch das Expenment Vol. 17: Part 1: Ions alcalino-terreux I. Systemes isohis Part 2: Ions alcalino-terreux II. Organismes entiers Vol. 18: PMt 1: Histamine Part 2: Anti-Histaminics Vol. 19: 5-Hydroxytryptamine and Related Indolealkylamines Vol. 20: Pharmacology of Fluorides Vol. 21: Beryllium Vol. 22: Die Gestagene Vol. 23: Neurohypophysial Hormones and Similar Polypeptides Vol. 24: DlUretica Vol. 25: Bradykinin, Kallidin, and Kallikrein Vol. 26: Vergleichende Pharmakologle von Obertragersubstanzen m tiersystematischer Darstellung Vol. 27: AntlcoagulantJen Vol. 28: Concepts in BIochemical Pharmacology Vol. 29: Oral wirksame Antidiabetika Vol. 30: Modern Inhalation Anesthetics Vol. 31: Antianginal Drugs Vol. 32: Insuhn Vol. 33: Catecholammes Vol. 34: Secretin, Cholecystokinin, Pancreozymin and Gastrin Vol. 35: Part 1: Androgene I Part 2: Androgens II and Antiandrogens Vol. 36: Uranium-Plutonium-Transplutomc Elements Vol. 37: Angiotensin Vol. 38: Antineoplastic and Immunosuppressive Agents Vol. 39: Antihypertensive Agents Vol. 40: Organic NItrates Vol. 41: Hypolipidemic Agents Vol. 42: Neuromuscular JunctIon

11 F.TH. v. BROCKE, O. HORNYKIEWICZ, E.B. SIGG The Pharmacology of Psychotherapeutic Drugs Translated and revised by E.B. Sigg VIII, 157 pages (Heidelberg Science Library, Vol. 8) Distribution rights for U.K., Commonwealth, and the Traditional British Market (excluding Canda): English Universities Press Ltd., London. The aim of the book is to summarize the enourmous development in the field of psychotherapeutic drugs from the introduction of chlorpromazine and reserpine in the early fifties to the present time. European Journal of Clinical Pharmacology PharmacolOgIa Clmica Managing Editors: H.J. Dengler, F. Gross The "European Journal of Clinical Pharmacology" accepts for publication original papers on all aspects of pharmacology and drug therapeutics in man. This heading comprises studies on pharmacokinetics, drug metabolism, and drug mteractions as well as therapeutic trials, reports on adverse reactions, and general problems in therapeutics. Methodological papers on the topics mentioned are welcome. Trends in the development and safe use of drugs, and structural aspects of clinical pharmacology, especially those common to various European countnes, are covered by edltonals and invited papers. Review articles on SpecIal problems related to clinical pharmacology or other fields of therapeutics are regularly ISSUed. The journal is mtended pnmarily to provide a means of communications in the rapidly developing field of chnlcal pharmacology and therapeutics. Psycho pharmacologia Managmg Editors: H. Barry III, J.O. Cole, M. Hamilton, E. Jacobsen, R.W. Russell "Psycho pharmacologia" provides a medium for the rapid pubhcatjon of scientific contnbutlons concerned WIth the analysis and synthesis of the effects of drugs on behavior, in the broadest sense of the term. Such contributions may be of a clinical nature, or they may deal WIth specialized investigations in the fields of experimental psychology, neurophysiology, neurochemistry, general pharmacology, and cognate disclpbnes.